Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1459-1468

  Ghoneim, Hazem E ^a,b,c   Mccullers, Jonathan A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Antibiotics; corticosteroids; dexamethasone; immunomodulation; influenza; pneumonia; Streptococcus pneumoniae

Indexed keywords

ALBUMIN; AMPICILLIN; DEXAMETHASONE SODIUM PHOSPHATE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL LOAD; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; BIOLUMINESCENCE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IN VIVO STUDY; INFLUENZA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ANTIBIOTICS; CORTICOSTEROIDS; DEXAMETHASONE; IMMUNOMODULATION; INFLUENZA; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADAPTIVE IMMUNITY; AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; KAPLAN-MEIER ESTIMATE; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; PNEUMONIA, PNEUMOCOCCAL;

EID: 84898857321     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit653     Document Type: Article

References (49)

1. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: Final data for 2004. Natl Vital Stat Rep 2007; 55:1-119
2. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151-61
3. McCullers JA. Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011; 16:123-35
4. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLOS One 2009; 4:e8540
5. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-70
6. Dagan R, Bhutta ZA, de Quadros CA, et al. The remaining challenge of pneumonia: The leading killer of children. Pediatr Infect Dis J 2011; 30:1-2
7. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19
8. Estenssoro E, Rios FG, Apezteguia C, et al. Pandemic 2009 influenza A in Argentina: A study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 2010; 182:41-8
9. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630-1
10. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010; 16:402-10
11. McCullers JA, English BK. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 2008; 3:397-404
12. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA. Tolllike receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011; 204:1358-66
13. Bradley JS, Byington CL, Shah SS, et al. The management of communityacquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-76
14. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199:311-9
15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-Acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2):S27-72
16. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148:245-54
17. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353:1711-23
18. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-Acquired pneumonia: A randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023-30
19. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-Acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-8
20. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71
21. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-Acquired pneumonia: A randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975-82
22. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe communityacquired pneumonia. A randomized controlled study. Chest 1993; 104:389-92
23. World Health Organization. Clinical Management of Human Infection with Pandemic (H1N1) 2009: Revised Guidance. Geneva: World Health Organization, 2009. http://www.who.int/csr/resources/ publications/swineflu/clinical-management- h1n1.pdf. (Accessed 23 July 2013
24. Matthay MA, Liu KD. Con: Corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am J Respir Crit Care Med 2011; 183:1127-8
25. Confalonieri M, Kodric M, Santagiuliana M, et al. To use or not to use corticosteroids for pneumoniä A clinician's perspective. Monaldi Arch Chest Dis 2012; 77:94-101
26. Annane D. Pro: The illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med 2011; 183:1125-6
27. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 2013; 191:1250-9
28. Francis KP, Yu J, Bellinger-Kawahara C, et al. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun 2001; 69:3350-8
29. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007; 2:240-9
30. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519-26
31. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23-43
32. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281:61-6
33. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76
34. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9
35. Chiou CC, Yu VL. Severe pneumococcal pneumonia: New strategies for management. Curr Opin Crit Care 2006; 12:470-6
36. Meijvis SC, van de Garde EM, Rijkers GT, Bos WJ. Treatment with anti-inflammatory drugs in community-Acquired pneumonia. J Intern Med 2012; 272:25-35
37. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-Acquired pneumonia: A systematic review. J Antimicrob Chemother 2008; 62:661-8
38. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-Acquired pneumonia: A randomized controlled trial. Crit Care 2011; 15:R96
39. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-Acquired pneumonia requiring hospitalization. Lung 2007; 185:249-55
40. Pfausler B, Schmutzhard E. Controversies in neurology, Vienna, 2012: Steroids in bacterial meningitis: No. J Neural Transm 2013; 120: 343-6
41. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane database Syst Rev 2013; 6: CD004405
42. Fritz D, Brouwer MC, van de Beek D. Dexamethasone and long-Term survival in bacterial meningitis. Neurology 2012; 79:2177-9
43. Su X, Wang L, Song Y, Bai C. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive care Med 2004; 30:133-40
44. Kim J, McKinley L, Siddiqui J, Bolgos GL, Remick DG. Prevention and reversal of pulmonary inflammation and airway hyperresponsiveness by dexamethasone treatment in a murine model of asthma induced by house dust. Am J Physiol Lung Cell Mol Physiol 2004; 287:L503-9
45. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13:579-86
46. Xu T, Qiao J, Zhao L, et al. Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. Eur Respir J 2009; 33:852-60
47. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22:659-61
48. Salluh JI, Povoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT. The role of corticosteroids in severe community-Acquired pneumonia: A systematic review. Crit Care 2008; 12:R76
49. Wickersham RM, Schweain SL, Scott JA, et al., eds. Drug Facts & Comparisons: Pocket Version 2009. 13th ed. St. Louis, MO: Lippincott Williams &Wilkins, 2008:171.